ArticleDrug and alcohol dependence2026
Variation in knowledge and attitudes among overdose prevention collaborations: Insights from fatality review teams.
Article in Drug and alcohol dependence, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundOverdose fatality review (OFR) teams use cross-sector case review to develop prevention recommendations. We examined whether members' overdose knowledge and attitudes toward methadone, buprenorphine, and harm reduction differed by institutional domain.
methodsWe analyzed cross-sectional survey data from 145 members of 18 Indiana OFR teams, classified as public health, treatment/recovery/social support (TRSS), or criminal-legal system (CLS). Outcomes included a modified 11-item Brief Opioid Overdose Knowledge questionnaire, 7-point medication effectiveness and acceptability ratings, and Harm Reduction Acceptability Scale scores, for which higher scores indicated less favorable attitudes. One-way ANOVAs with Tukey-adjusted comparisons assessed domain differences.
resultsMean knowledge clustered near the maximum (9.3 of 11) and total and subscale scores did not differ by domain. Public health and TRSS respondents rated methadone (mean differences, 1.50 and 1.19) and buprenorphine (1.79 and 1.06) more effective than CLS respondents (all p < 0.01). Public health respondents rated methadone (1.26, p = 0.02) and buprenorphine (1.29, p < 0.01) more acceptable. CLS respondents reported less favorable harm reduction attitudes than public health and TRSS respondents (differences, 10.69 and 12.47; p = 0.02 and p < 0.01, respectively).
conclusionsAmong Indiana OFR members, institutional domain was associated with medication and harm reduction attitudes, but not measured overdose knowledge. The null knowledge finding warrants caution given the apparent ceiling effect. Domain-specific concerns merit consideration in cross-sector implementation efforts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.